Australian digital clinical trial recruitment company Opyl has signed agreements with two patient advocacy groups.
The agreements with Neuroendocrine Cancer Australia and Pancare Foundation aim to facilitate the rapid recruitment of patients in new trials via Opyl's Opin digital platform.
Opin uses artificial intelligence to match patients in its database to appropriate trials.
The new agreements will help ensure that the patient communities represented by Neuroendocrine Cancer Australia and Pancare Foundation are aware of every active, relevant clinical trial and are given every opportunity to participate in those trials.
“Our approach is to ensure Opin is genuinely of value to patients and to do this we need their input into our technology and service design,” said Opyl CEO Michelle Gallaher.
“The Opin clinical trial recruitment team are very excited to work with Neuroendocrine Cancer Australia and Pancare Foundation. I think we have a lot to learn from and offer each other.”